New ASPS Clinical Trial: Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
New clinical trial for ASPS is expected to open on March 2016. Study number: NCT02636725 This is a phase II clinical trial that combines treatment with Axitinib and Pembrolizumab in patients with advanced Alveolar Soft Part Sarcoma (ASPS) and other soft tissue sarcomas. Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor. […]